Brazil Maintains Rapid Growth with Healthcare Market Development Revenue from obesity GLP-1 treatment in Brazil is growing at a CAGR of 28.9%, driven by expanding private health insurance coverage and increasing physician adoption of obesity pharmacotherapy
Lynda Scammell, the head of borderline products at the MHRA, said: Peptide products may be sold as cosmetics, supplements and medicines, and depending on their intended purpose, they fall under different regulatory frameworks
Pricing tends to fluctuate according to format, pharmacy, and dosing
Under current TRICARE guidance, beneficiaries using TRICARE For Life are not eligible for coverage of weight-loss medications like Wegovy
Semaglutide, a medication used for weight management and type 2 diabetes, is associated with various side effects
However, uptake transporter assays indicated that ATSP-7041 acts as both a substrate for OATPs and a potent inhibitor of OATP1B1 (IC 50 : 0.81 M), suggesting the potential for clinically relevant DDIs